| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| GH - Guardant Health Inc | BUY | 1,040 @ USD 93.02 | USD 96,741 | The ETF bought 1040 new shares of GH (Guardant Health Inc). The shares were bought for an average price of 93.02 compared to the previous average buy price of 52.1729. This is 78.3% higher than average price of previous purchases of GH. |
| APLS - Apellis Pharmaceuticals Inc | BUY | 1,060 @ USD 21.47 | USD 22,758 | The ETF bought 1060 new shares of APLS (Apellis Pharmaceuticals Inc). The shares were bought for an average price of 21.47 compared to the previous average buy price of 21.0165. This is 2.2% higher than average price of previous purchases of APLS. |
| VNDA - Vanda Pharmaceuticals Inc | BUY | 545 @ USD 4.35 | USD 2,371 | The ETF bought 545 new shares of VNDA (Vanda Pharmaceuticals Inc). The shares were bought for an average price of 4.35 compared to the previous average buy price of 4.88335. This is -10.9% lower than average price of previous purchases of VNDA. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 5.55 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 5.55. The average price that ABCL shares were previous bought at was USD 3.91623. The current market price is 41.7% higher than average price they were purchased at. The value of the holding in ABCL has increased by USD 36,180 compared to the previous valuation of Abcellera Biologics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| ABUS - Arbutus Biopharma Corp | HOLD | 0 @ USD 4.73 | USD 0 | The current share valuation price of ABUS based on adjusted close was USD 4.73. The average price that ABUS shares were previous bought at was USD 3.59733. The current market price is 31.5% higher than average price they were purchased at. The value of the holding in ABUS has fallen by USD 13,686 compared to the previous valuation of Arbutus Biopharma Corp |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 22.7 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 22.7. The average price that ACAD shares were previous bought at was USD 20.782. The current market price is 9.2% higher than average price they were purchased at. The value of the holding in ACAD has fallen by USD 4,365 compared to the previous valuation of ACADIA Pharmaceuticals Inc |
| ACIU - AC Immune Ltd | HOLD | 0 @ USD 3.38001 | USD 0 | The current share valuation price of ACIU based on adjusted close was USD 3.38001. The average price that ACIU shares were previous bought at was USD 2.35576. The current market price is 43.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of AC Immune Ltd |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 90.25 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 90.25. The average price that ACLX shares were previous bought at was USD 71.4398. The current market price is 26.3% higher than average price they were purchased at. The value of the holding in ACLX has increased by USD 98,128 compared to the previous valuation of Arcellx Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| ADMA - ADMA Biologics Inc | HOLD | 0 @ USD 15.48 | USD 0 | The current share valuation price of ADMA based on adjusted close was USD 15.48. The average price that ADMA shares were previous bought at was USD 17.4723. The current market price is -11.4% lower than average price they were purchased at. The value of the holding in ADMA has increased by USD 32,413 compared to the previous valuation of ADMA Biologics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 17.36 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 17.36. The average price that ADPT shares were previous bought at was USD 11.7367. The current market price is 47.9% higher than average price they were purchased at. The value of the holding in ADPT has increased by USD 43,636 compared to the previous valuation of Adaptive Biotechnologies Corp however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| AGIO - Agios Pharm | HOLD | 0 @ USD 43.24 | USD 0 | The current share valuation price of AGIO based on adjusted close was USD 43.24. The average price that AGIO shares were previous bought at was USD 35.7678. The current market price is 20.9% higher than average price they were purchased at. The value of the holding in AGIO has increased by USD 2,220 compared to the previous valuation of Agios Pharm however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| AKRO - Akero Therapeutics Inc | HOLD | 0 @ USD 54.2 | USD 0 | The current share valuation price of AKRO based on adjusted close was USD 54.2. The average price that AKRO shares were previous bought at was USD 49.1076. The current market price is 10.4% higher than average price they were purchased at. The value of the holding in AKRO has fallen by USD 3,095 compared to the previous valuation of Akero Therapeutics Inc |
| ALEC - Alector Inc | HOLD | 0 @ USD 1.47 | USD 0 | The current share valuation price of ALEC based on adjusted close was USD 1.47. The average price that ALEC shares were previous bought at was USD 1.95226. The current market price is -24.7% lower than average price they were purchased at. The value of the holding in ALEC has fallen by USD 3,388 compared to the previous valuation of Alector Inc |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 30.7 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 30.7. The average price that ALKS shares were previous bought at was USD 30.3896. The current market price is 1.0% higher than average price they were purchased at. The value of the holding in ALKS has fallen by USD 12,744 compared to the previous valuation of Alkermes Plc |
| ALLO - Allogene Therapeutics Inc | HOLD | 0 @ USD 1.24 | USD 0 | The current share valuation price of ALLO based on adjusted close was USD 1.24. The average price that ALLO shares were previous bought at was USD 1.33808. The current market price is -7.3% lower than average price they were purchased at. The value of the holding in ALLO has increased by USD 4,191 compared to the previous valuation of Allogene Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 456.04 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 456.04. The average price that ALNY shares were previous bought at was USD 372.61. The current market price is 22.4% higher than average price they were purchased at. The value of the holding in ALNY has increased by USD 541,754 compared to the previous valuation of Alnylam Pharmaceuticals Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| ALT - Altitude Group Plc | HOLD | 0 @ USD 4.05001 | USD 0 | The current share valuation price of ALT based on adjusted close was USD 4.05001. The average price that ALT shares were previous bought at was USD 5.21518. The current market price is -22.3% lower than average price they were purchased at. The value of the holding in ALT has fallen by USD 1,085 compared to the previous valuation of Altitude Group Plc |
| AMGN - Amgen Inc | HOLD | 0 @ USD 298.43 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 298.43. The average price that AMGN shares were previous bought at was USD 286.546. The current market price is 4.1% higher than average price they were purchased at. The value of the holding in AMGN has increased by USD 1,189,415 compared to the previous valuation of Amgen Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 13.93 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 13.93. The average price that AMLX shares were previous bought at was USD 6.78109. The current market price is 105.4% higher than average price they were purchased at. The value of the holding in AMLX has fallen by USD 6,818 compared to the previous valuation of Amylyx Pharmaceuticals Inc |
| AMPH - Amphastar P | HOLD | 0 @ USD 25.5 | USD 0 | The current share valuation price of AMPH based on adjusted close was USD 25.5. The average price that AMPH shares were previous bought at was USD 25.4441. The current market price is 0.2% higher than average price they were purchased at. The value of the holding in AMPH has increased by USD 24,874 compared to the previous valuation of Amphastar P however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | HOLD | 0 @ USD 10.82 | USD 0 | The current share valuation price of AMRX based on adjusted close was USD 10.82. The average price that AMRX shares were previous bought at was USD 8.70595. The current market price is 24.3% higher than average price they were purchased at. The value of the holding in AMRX has increased by USD 166,833 compared to the previous valuation of Amneal Pharmaceuticals, Inc. Class A Common Stock however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 36.58 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 36.58. The average price that ANAB shares were previous bought at was USD 23.7388. The current market price is 54.1% higher than average price they were purchased at. The value of the holding in ANAB has increased by USD 1,962 compared to the previous valuation of AnaptysBio Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| ANIP - ANI Pharmaceuticals Inc | HOLD | 0 @ USD 90.6 | USD 0 | The current share valuation price of ANIP based on adjusted close was USD 90.6. The average price that ANIP shares were previous bought at was USD 71.2104. The current market price is 27.2% higher than average price they were purchased at. The value of the holding in ANIP has fallen by USD 18,382 compared to the previous valuation of ANI Pharmaceuticals Inc |
| APGE - Apogee Therapeutics, Inc. Common Stock | HOLD | 0 @ USD 56.59 | USD 0 | The current share valuation price of APGE based on adjusted close was USD 56.59. The average price that APGE shares were previous bought at was USD 43.14. The current market price is 31.2% higher than average price they were purchased at. The value of the holding in APGE has increased by USD 16,146 compared to the previous valuation of Apogee Therapeutics, Inc. Common Stock however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 9.97003 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 9.97003. The average price that ARCT shares were previous bought at was USD 14.7974. The current market price is -32.6% lower than average price they were purchased at. The value of the holding in ARCT has increased by USD 6,182 compared to the previous valuation of Arcturus Therapeutics Holdings Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| ARDX - Ardelyx Inc | HOLD | 0 @ USD 6.06 | USD 0 | The current share valuation price of ARDX based on adjusted close was USD 6.06. The average price that ARDX shares were previous bought at was USD 4.5835. The current market price is 32.2% higher than average price they were purchased at. The value of the holding in ARDX has increased by USD 161,269 compared to the previous valuation of Ardelyx Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| ARGX - argenx NV ADR | HOLD | 0 @ USD 818.5 | USD 0 | The current share valuation price of ARGX based on adjusted close was USD 818.5. The average price that ARGX shares were previous bought at was USD 629.717. The current market price is 30.0% higher than average price they were purchased at. The value of the holding in ARGX has fallen by USD 36,628 compared to the previous valuation of argenx NV ADR |
| ARQT - Arcutis Biotherapeutics Inc | HOLD | 0 @ USD 25.31 | USD 0 | The current share valuation price of ARQT based on adjusted close was USD 25.31. The average price that ARQT shares were previous bought at was USD 15.8926. The current market price is 59.3% higher than average price they were purchased at. The value of the holding in ARQT has increased by USD 29,778 compared to the previous valuation of Arcutis Biotherapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 10.14 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 10.14. The average price that ARVN shares were previous bought at was USD 8.69221. The current market price is 16.7% higher than average price they were purchased at. The value of the holding in ARVN has increased by USD 9,598 compared to the previous valuation of Arvinas Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| ARWR - Arrowhead Pharmaceuticals Inc | HOLD | 0 @ USD 42.39 | USD 0 | The current share valuation price of ARWR based on adjusted close was USD 42.39. The average price that ARWR shares were previous bought at was USD 20.6079. The current market price is 105.7% higher than average price they were purchased at. The value of the holding in ARWR has increased by USD 7,119 compared to the previous valuation of Arrowhead Pharmaceuticals Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| ASND - Ascendis Pharma AS | HOLD | 0 @ USD 201.6 | USD 0 | The current share valuation price of ASND based on adjusted close was USD 201.6. The average price that ASND shares were previous bought at was USD 176.789. The current market price is 14.0% higher than average price they were purchased at. The value of the holding in ASND has fallen by USD 82,396 compared to the previous valuation of Ascendis Pharma AS |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 13.17 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 13.17. The average price that AUPH shares were previous bought at was USD 8.89631. The current market price is 48.0% higher than average price they were purchased at. The value of the holding in AUPH has increased by USD 88,066 compared to the previous valuation of Aurinia Pharmaceuticals Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| AUTL - Autolus Therapeutics Ltd | HOLD | 0 @ USD 1.55 | USD 0 | The current share valuation price of AUTL based on adjusted close was USD 1.55. The average price that AUTL shares were previous bought at was USD 1.86751. The current market price is -17.0% lower than average price they were purchased at. The value of the holding in AUTL has increased by USD 5,544 compared to the previous valuation of Autolus Therapeutics Ltd however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| AVDL - Avadel Pharmaceuticals PLC | HOLD | 0 @ USD 18.89 | USD 0 | The current share valuation price of AVDL based on adjusted close was USD 18.89. The average price that AVDL shares were previous bought at was USD 10.6406. The current market price is 77.5% higher than average price they were purchased at. The value of the holding in AVDL has increased by USD 3,712 compared to the previous valuation of Avadel Pharmaceuticals PLC however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| AVIR - Atea Pharmaceuticals Inc | HOLD | 0 @ USD 3.25 | USD 0 | The current share valuation price of AVIR based on adjusted close was USD 3.25. The average price that AVIR shares were previous bought at was USD 3.34571. The current market price is -2.9% lower than average price they were purchased at. The value of the holding in AVIR has fallen by USD 1,069 compared to the previous valuation of Atea Pharmaceuticals Inc |
| AVXL - Anavex Life Sciences Corp | HOLD | 0 @ USD 7.97001 | USD 0 | The current share valuation price of AVXL based on adjusted close was USD 7.97001. The average price that AVXL shares were previous bought at was USD 9.63603. The current market price is -17.3% lower than average price they were purchased at. The value of the holding in AVXL has fallen by USD 3,286 compared to the previous valuation of Anavex Life Sciences Corp |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 134.99 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 134.99. The average price that AXSM shares were previous bought at was USD 113.632. The current market price is 18.8% higher than average price they were purchased at. The value of the holding in AXSM has increased by USD 58,948 compared to the previous valuation of Axsome Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| AZN - AstraZeneca PLC | HOLD | 0 @ USD 82.4 | USD 0 | The current share valuation price of AZN based on adjusted close was USD 82.4. The average price that AZN shares were previous bought at was USD 74.3491. The current market price is 10.8% higher than average price they were purchased at. The value of the holding in AZN has increased by USD 19,982 compared to the previous valuation of AstraZeneca PLC however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| BBIO - BridgeBio Pharma Inc | HOLD | 0 @ USD 62.64 | USD 0 | The current share valuation price of BBIO based on adjusted close was USD 62.64. The average price that BBIO shares were previous bought at was USD 43.9553. The current market price is 42.5% higher than average price they were purchased at. The value of the holding in BBIO has fallen by USD 89,970 compared to the previous valuation of BridgeBio Pharma Inc |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 7.32 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 7.32. The average price that BCRX shares were previous bought at was USD 8.34427. The current market price is -12.3% lower than average price they were purchased at. The value of the holding in BCRX has increased by USD 9,363 compared to the previous valuation of BioCryst Pharmaceuticals Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| BCYC - Bicycle Therapeutics Ltd | HOLD | 0 @ USD 8.06999 | USD 0 | The current share valuation price of BCYC based on adjusted close was USD 8.06999. The average price that BCYC shares were previous bought at was USD 8.61609. The current market price is -6.3% lower than average price they were purchased at. The value of the holding in BCYC has fallen by USD 20,852 compared to the previous valuation of Bicycle Therapeutics Ltd |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 25.01 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 25.01. The average price that BEAM shares were previous bought at was USD 20.5495. The current market price is 21.7% higher than average price they were purchased at. The value of the holding in BEAM has increased by USD 77,932 compared to the previous valuation of Beam Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 154.27 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 154.27. The average price that BIIB shares were previous bought at was USD 137.307. The current market price is 12.4% higher than average price they were purchased at. The value of the holding in BIIB has increased by USD 439,522 compared to the previous valuation of Biogen Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| BMEA - Biomea Fusion Inc | HOLD | 0 @ USD 1.36001 | USD 0 | The current share valuation price of BMEA based on adjusted close was USD 1.36001. The average price that BMEA shares were previous bought at was USD 1.83183. The current market price is -25.8% lower than average price they were purchased at. The value of the holding in BMEA has increased by USD 1,327 compared to the previous valuation of Biomea Fusion Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| BMRN - Biomarin Pharmaceutical Inc | HOLD | 0 @ USD 53.57 | USD 0 | The current share valuation price of BMRN based on adjusted close was USD 53.57. The average price that BMRN shares were previous bought at was USD 58.4179. The current market price is -8.3% lower than average price they were purchased at. The value of the holding in BMRN has increased by USD 204,506 compared to the previous valuation of Biomarin Pharmaceutical Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| BNTX - BioNTech SE | HOLD | 0 @ USD 103.91 | USD 0 | The current share valuation price of BNTX based on adjusted close was USD 103.91. The average price that BNTX shares were previous bought at was USD 105.308. The current market price is -1.3% lower than average price they were purchased at. The value of the holding in BNTX has fallen by USD 49,058 compared to the previous valuation of BioNTech SE |
| CGEM - Cullinan Oncology LLC | HOLD | 0 @ USD 8.66001 | USD 0 | The current share valuation price of CGEM based on adjusted close was USD 8.66001. The average price that CGEM shares were previous bought at was USD 7.86821. The current market price is 10.1% higher than average price they were purchased at. The value of the holding in CGEM has increased by USD 42,891 compared to the previous valuation of Cullinan Oncology LLC however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 43.27 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 43.27. The average price that CGON shares were previous bought at was USD 29.5752. The current market price is 46.3% higher than average price they were purchased at. The value of the holding in CGON has increased by USD 39,472 compared to the previous valuation of CG Oncology, Inc. Common stock however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| CNTA - Centessa Pharmaceuticals PLC ADR | HOLD | 0 @ USD 24.9 | USD 0 | The current share valuation price of CNTA based on adjusted close was USD 24.9. The average price that CNTA shares were previous bought at was USD 16.2701. The current market price is 53.0% higher than average price they were purchased at. The value of the holding in CNTA has increased by USD 34,815 compared to the previous valuation of Centessa Pharmaceuticals PLC ADR however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| COGT - Cogent Biosciences Inc | HOLD | 0 @ USD 16.3 | USD 0 | The current share valuation price of COGT based on adjusted close was USD 16.3. The average price that COGT shares were previous bought at was USD 10.6024. The current market price is 53.7% higher than average price they were purchased at. The value of the holding in COGT has increased by USD 8,004 compared to the previous valuation of Cogent Biosciences Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| COLL - Collegium Pharmaceutical Inc | HOLD | 0 @ USD 36 | USD 0 | The current share valuation price of COLL based on adjusted close was USD 36. The average price that COLL shares were previous bought at was USD 31.2957. The current market price is 15.0% higher than average price they were purchased at. The value of the holding in COLL has increased by USD 7,023 compared to the previous valuation of Collegium Pharmaceutical Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| CRNX - Crinetics Pharmaceuticals Inc | HOLD | 0 @ USD 43.5 | USD 0 | The current share valuation price of CRNX based on adjusted close was USD 43.5. The average price that CRNX shares were previous bought at was USD 34.6228. The current market price is 25.6% higher than average price they were purchased at. The value of the holding in CRNX has increased by USD 13,358 compared to the previous valuation of Crinetics Pharmaceuticals Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| CRSP - Crispr Therapeutics AG | HOLD | 0 @ USD 63.99 | USD 0 | The current share valuation price of CRSP based on adjusted close was USD 63.99. The average price that CRSP shares were previous bought at was USD 52.4668. The current market price is 22.0% higher than average price they were purchased at. The value of the holding in CRSP has increased by USD 168,648 compared to the previous valuation of Crispr Therapeutics AG however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 25.5 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 25.5. The average price that CSTL shares were previous bought at was USD 21.1566. The current market price is 20.5% higher than average price they were purchased at. The value of the holding in CSTL has increased by USD 23,924 compared to the previous valuation of Castle Biosciences Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| CVAC - CureVac NV | HOLD | 0 @ USD 5.34 | USD 0 | The current share valuation price of CVAC based on adjusted close was USD 5.34. The average price that CVAC shares were previous bought at was USD 4.82813. The current market price is 10.6% higher than average price they were purchased at. The value of the holding in CVAC has fallen by USD 2,870 compared to the previous valuation of CureVac NV |
| CYTK - Cytokinetics Inc | HOLD | 0 @ USD 63.59 | USD 0 | The current share valuation price of CYTK based on adjusted close was USD 63.59. The average price that CYTK shares were previous bought at was USD 41.9783. The current market price is 51.5% higher than average price they were purchased at. The value of the holding in CYTK has increased by USD 102,877 compared to the previous valuation of Cytokinetics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 7.44 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 7.44. The average price that DAWN shares were previous bought at was USD 7.37138. The current market price is 0.9% higher than average price they were purchased at. The value of the holding in DAWN has increased by USD 25,915 compared to the previous valuation of Day One Biopharmaceuticals Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| DNLI - Denali Therapeutics Inc | HOLD | 0 @ USD 16.28 | USD 0 | The current share valuation price of DNLI based on adjusted close was USD 16.28. The average price that DNLI shares were previous bought at was USD 15.0862. The current market price is 7.9% higher than average price they were purchased at. The value of the holding in DNLI has fallen by USD 9,311 compared to the previous valuation of Denali Therapeutics Inc |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 10.26 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 10.26. The average price that DVAX shares were previous bought at was USD 10.4637. The current market price is -1.9% lower than average price they were purchased at. The value of the holding in DVAX has fallen by USD 10,464 compared to the previous valuation of Dynavax Technologies Corporation |
| DYN - Dyne Therapeutics Inc | HOLD | 0 @ USD 22.58 | USD 0 | The current share valuation price of DYN based on adjusted close was USD 22.58. The average price that DYN shares were previous bought at was USD 12.6718. The current market price is 78.2% higher than average price they were purchased at. The value of the holding in DYN has fallen by USD 89,312 compared to the previous valuation of Dyne Therapeutics Inc |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | HOLD | 0 @ USD 22.58 | USD 0 | The current share valuation price of DYN based on adjusted close was USD 22.58. The average price that DYN shares were previous bought at was USD 12.6718. The current market price is 78.2% higher than average price they were purchased at. The value of the holding in DYN has fallen by USD 89,312 compared to the previous valuation of DYNAGREEN EN.PR.GR.H YC 1 |
| EDIT - Editas Medicine Inc | HOLD | 0 @ USD 3.08 | USD 0 | The current share valuation price of EDIT based on adjusted close was USD 3.08. The average price that EDIT shares were previous bought at was USD 2.74627. The current market price is 12.2% higher than average price they were purchased at. The value of the holding in EDIT has increased by USD 4,280 compared to the previous valuation of Editas Medicine Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| ELVN - Enliven Therapeutics Inc. | HOLD | 0 @ USD 23.42 | USD 0 | The current share valuation price of ELVN based on adjusted close was USD 23.42. The average price that ELVN shares were previous bought at was USD 20.3892. The current market price is 14.9% higher than average price they were purchased at. The value of the holding in ELVN has fallen by USD 20,740 compared to the previous valuation of Enliven Therapeutics Inc. |
| EOLS - Evolus Inc | HOLD | 0 @ USD 6.46 | USD 0 | The current share valuation price of EOLS based on adjusted close was USD 6.46. The average price that EOLS shares were previous bought at was USD 9.26816. The current market price is -30.3% lower than average price they were purchased at. The value of the holding in EOLS has fallen by USD 11,619 compared to the previous valuation of Evolus Inc |
| ERAS - Erasca Inc | HOLD | 0 @ USD 2.42 | USD 0 | The current share valuation price of ERAS based on adjusted close was USD 2.42. The average price that ERAS shares were previous bought at was USD 1.6246. The current market price is 49.0% higher than average price they were purchased at. The value of the holding in ERAS has fallen by USD 7,734 compared to the previous valuation of Erasca Inc |
| EWTX - Edgewise Therapeutics Inc | HOLD | 0 @ USD 18.28 | USD 0 | The current share valuation price of EWTX based on adjusted close was USD 18.28. The average price that EWTX shares were previous bought at was USD 15.734. The current market price is 16.2% higher than average price they were purchased at. The value of the holding in EWTX has fallen by USD 26,171 compared to the previous valuation of Edgewise Therapeutics Inc |
| EXEL - Exelixis Inc | HOLD | 0 @ USD 38.67 | USD 0 | The current share valuation price of EXEL based on adjusted close was USD 38.67. The average price that EXEL shares were previous bought at was USD 40.9211. The current market price is -5.5% lower than average price they were purchased at. The value of the holding in EXEL has fallen by USD 46,639 compared to the previous valuation of Exelixis Inc |
| EYPT - Eyepoint Pharmaceuticals Inc | HOLD | 0 @ USD 13.09 | USD 0 | The current share valuation price of EYPT based on adjusted close was USD 13.09. The average price that EYPT shares were previous bought at was USD 8.66511. The current market price is 51.1% higher than average price they were purchased at. The value of the holding in EYPT has increased by USD 38,660 compared to the previous valuation of Eyepoint Pharmaceuticals Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| FATE - Fate Therapeutics Inc | HOLD | 0 @ USD 1.35 | USD 0 | The current share valuation price of FATE based on adjusted close was USD 1.35. The average price that FATE shares were previous bought at was USD 1.19222. The current market price is 13.2% higher than average price they were purchased at. The value of the holding in FATE has increased by USD 4,165 compared to the previous valuation of Fate Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| FDMT - 4D Molecular Therapeutics Inc | HOLD | 0 @ USD 11.5 | USD 0 | The current share valuation price of FDMT based on adjusted close was USD 11.5. The average price that FDMT shares were previous bought at was USD 6.06174. The current market price is 89.7% higher than average price they were purchased at. The value of the holding in FDMT has increased by USD 5,743 compared to the previous valuation of 4D Molecular Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| FOLD - Amicus Therapeutics Inc | HOLD | 0 @ USD 9.03 | USD 0 | The current share valuation price of FOLD based on adjusted close was USD 9.03. The average price that FOLD shares were previous bought at was USD 7.28246. The current market price is 24.0% higher than average price they were purchased at. The value of the holding in FOLD has increased by USD 25,518 compared to the previous valuation of Amicus Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 10.46 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 10.46. The average price that FTRE shares were previous bought at was USD 6.46477. The current market price is 61.8% higher than average price they were purchased at. The value of the holding in FTRE has increased by USD 24,890 compared to the previous valuation of Fortrea Holdings Inc. however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| GERN - Geron Corporation | HOLD | 0 @ USD 1.26 | USD 0 | The current share valuation price of GERN based on adjusted close was USD 1.26. The average price that GERN shares were previous bought at was USD 1.51961. The current market price is -17.1% lower than average price they were purchased at. The value of the holding in GERN has increased by USD 8,051 compared to the previous valuation of Geron Corporation however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 119.79 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 119.79. The average price that GILD shares were previous bought at was USD 112.398. The current market price is 6.6% higher than average price they were purchased at. The value of the holding in GILD has increased by USD 635,993 compared to the previous valuation of Guild Esports Plc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| GLPG - Galapagos NV ADR | HOLD | 0 @ USD 31.78 | USD 0 | The current share valuation price of GLPG based on adjusted close was USD 31.78. The average price that GLPG shares were previous bought at was USD 29.0888. The current market price is 9.3% higher than average price they were purchased at. The value of the holding in GLPG has increased by USD 4,248 compared to the previous valuation of Galapagos NV ADR however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| GLPG - Galapagos N.V. | HOLD | 0 @ USD 31.78 | USD 0 | The current share valuation price of GLPG based on adjusted close was USD 31.78. The average price that GLPG shares were previous bought at was USD 29.0888. The current market price is 9.3% higher than average price they were purchased at. The value of the holding in GLPG has increased by USD 4,248 compared to the previous valuation of Galapagos N.V. however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| GMAB - Genmab AS | HOLD | 0 @ USD 28.61 | USD 0 | The current share valuation price of GMAB based on adjusted close was USD 28.61. The average price that GMAB shares were previous bought at was USD 23.1937. The current market price is 23.4% higher than average price they were purchased at. The value of the holding in GMAB has fallen by USD 1,602 compared to the previous valuation of Genmab AS |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | HOLD | 0 @ USD 33.32 | USD 0 | The current share valuation price of GPCR based on adjusted close was USD 33.32. The average price that GPCR shares were previous bought at was USD 22.5853. The current market price is 47.5% higher than average price they were purchased at. The value of the holding in GPCR has increased by USD 41,736 compared to the previous valuation of Structure Therapeutics Inc. American Depositary Shares however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| GRAL - GRAIL, LLC | HOLD | 0 @ USD 91.93 | USD 0 | The current share valuation price of GRAL based on adjusted close was USD 91.93. The average price that GRAL shares were previous bought at was USD 51.3136. The current market price is 79.2% higher than average price they were purchased at. The value of the holding in GRAL has increased by USD 18,228 compared to the previous valuation of GRAIL, LLC however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| GRFS - Grifols SA ADR | HOLD | 0 @ USD 9.37001 | USD 0 | The current share valuation price of GRFS based on adjusted close was USD 9.37001. The average price that GRFS shares were previous bought at was USD 9.46975. The current market price is -1.1% lower than average price they were purchased at. The value of the holding in GRFS has increased by USD 16,332 compared to the previous valuation of Grifols SA ADR however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 65.19 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 65.19. The average price that HALO shares were previous bought at was USD 59.2165. The current market price is 10.1% higher than average price they were purchased at. The value of the holding in HALO has increased by USD 42,026 compared to the previous valuation of Halozyme Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| HCM - HUTCHMED China Ltd | HOLD | 0 @ USD 14.68 | USD 0 | The current share valuation price of HCM based on adjusted close was USD 14.68. The average price that HCM shares were previous bought at was USD 15.5111. The current market price is -5.4% lower than average price they were purchased at. The value of the holding in HCM has increased by USD 5,071 compared to the previous valuation of HUTCHMED China Ltd however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| HCM - Hitachi Construction Machinery Co. Ltd | HOLD | 0 @ USD 14.68 | USD 0 | The current share valuation price of HCM based on adjusted close was USD 14.68. The average price that HCM shares were previous bought at was USD 15.5111. The current market price is -5.4% lower than average price they were purchased at. The value of the holding in HCM has increased by USD 5,071 compared to the previous valuation of Hitachi Construction Machinery Co. Ltd however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 28.57 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 28.57. The average price that HRMY shares were previous bought at was USD 31.8388. The current market price is -10.3% lower than average price they were purchased at. The value of the holding in HRMY has fallen by USD 12,092 compared to the previous valuation of Harmony Biosciences Holdings |
| HROW - Harrow Health Inc | HOLD | 0 @ USD 37.77 | USD 0 | The current share valuation price of HROW based on adjusted close was USD 37.77. The average price that HROW shares were previous bought at was USD 33.2175. The current market price is 13.7% higher than average price they were purchased at. The value of the holding in HROW has increased by USD 4,946 compared to the previous valuation of Harrow Health Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| HUMA - Humacyte Inc | HOLD | 0 @ USD 1.67 | USD 0 | The current share valuation price of HUMA based on adjusted close was USD 1.67. The average price that HUMA shares were previous bought at was USD 2.2409. The current market price is -25.5% lower than average price they were purchased at. The value of the holding in HUMA has increased by USD 5,184 compared to the previous valuation of Humacyte Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.4 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.4. The average price that IBRX shares were previous bought at was USD 2.77559. The current market price is -13.5% lower than average price they were purchased at. The value of the holding in IBRX has increased by USD 24,425 compared to the previous valuation of Immunitybio Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 31.86 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 31.86. The average price that IDYA shares were previous bought at was USD 23.0599. The current market price is 38.2% higher than average price they were purchased at. The value of the holding in IDYA has increased by USD 14,808 compared to the previous valuation of Ideaya Biosciences Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| ILMN - Illumina Inc | HOLD | 0 @ USD 123.54 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 123.54. The average price that ILMN shares were previous bought at was USD 96.503. The current market price is 28.0% higher than average price they were purchased at. The value of the holding in ILMN has increased by USD 2,419,149 compared to the previous valuation of Illumina Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| IMCR - Immunocore Holdings Ltd | HOLD | 0 @ USD 33.09 | USD 0 | The current share valuation price of IMCR based on adjusted close was USD 33.09. The average price that IMCR shares were previous bought at was USD 32.6574. The current market price is 1.3% higher than average price they were purchased at. The value of the holding in IMCR has increased by USD 23,586 compared to the previous valuation of Immunocore Holdings Ltd however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| IMVT - Immunovant Inc | HOLD | 0 @ USD 24.68 | USD 0 | The current share valuation price of IMVT based on adjusted close was USD 24.68. The average price that IMVT shares were previous bought at was USD 17.8386. The current market price is 38.4% higher than average price they were purchased at. The value of the holding in IMVT has fallen by USD 15,827 compared to the previous valuation of Immunovant Inc |
| INCY - Incyte Corporation | HOLD | 0 @ USD 93.48 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 93.48. The average price that INCY shares were previous bought at was USD 73.0429. The current market price is 28.0% higher than average price they were purchased at. The value of the holding in INCY has increased by USD 111,871 compared to the previous valuation of Incyte Corporation however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| INSM - Insmed Inc | HOLD | 0 @ USD 189.6 | USD 0 | The current share valuation price of INSM based on adjusted close was USD 189.6. The average price that INSM shares were previous bought at was USD 117.5. The current market price is 61.4% higher than average price they were purchased at. The value of the holding in INSM has fallen by USD 628,039 compared to the previous valuation of Insmed Inc |
| INVA - Innoviva Inc | HOLD | 0 @ USD 18.2 | USD 0 | The current share valuation price of INVA based on adjusted close was USD 18.2. The average price that INVA shares were previous bought at was USD 18.8346. The current market price is -3.4% lower than average price they were purchased at. The value of the holding in INVA has increased by USD 9,980 compared to the previous valuation of Innoviva Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| IONS - Ionis Pharmaceuticals Inc | HOLD | 0 @ USD 74.3 | USD 0 | The current share valuation price of IONS based on adjusted close was USD 74.3. The average price that IONS shares were previous bought at was USD 47.26. The current market price is 57.2% higher than average price they were purchased at. The value of the holding in IONS has increased by USD 13,361 compared to the previous valuation of Ionis Pharmaceuticals Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 1.97 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 1.97. The average price that IOVA shares were previous bought at was USD 2.44149. The current market price is -19.3% lower than average price they were purchased at. The value of the holding in IOVA has increased by USD 4,522 compared to the previous valuation of Iovance Biotherapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| IRON - Ironveld Plc | HOLD | 0 @ USD 86.22 | USD 0 | The current share valuation price of IRON based on adjusted close was USD 86.22. The average price that IRON shares were previous bought at was USD 58.11. The current market price is 48.4% higher than average price they were purchased at. The value of the holding in IRON has increased by USD 10,592 compared to the previous valuation of Ironveld Plc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| IRWD - Ironwood Pharmaceuticals Inc | HOLD | 0 @ USD 1.92 | USD 0 | The current share valuation price of IRWD based on adjusted close was USD 1.92. The average price that IRWD shares were previous bought at was USD 1.10524. The current market price is 73.7% higher than average price they were purchased at. The value of the holding in IRWD has increased by USD 40,910 compared to the previous valuation of Ironwood Pharmaceuticals Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 28.71 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 28.71. The average price that JANX shares were previous bought at was USD 27.6634. The current market price is 3.8% higher than average price they were purchased at. The value of the holding in JANX has increased by USD 7,655 compared to the previous valuation of Janux Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| JAZZ - Jazz Pharmaceuticals PLC | HOLD | 0 @ USD 137.64 | USD 0 | The current share valuation price of JAZZ based on adjusted close was USD 137.64. The average price that JAZZ shares were previous bought at was USD 121.112. The current market price is 13.6% higher than average price they were purchased at. The value of the holding in JAZZ has increased by USD 52,155 compared to the previous valuation of Jazz Pharmaceuticals PLC however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| KALV - Kalvista Pharmaceuticals Inc | HOLD | 0 @ USD 10.91 | USD 0 | The current share valuation price of KALV based on adjusted close was USD 10.91. The average price that KALV shares were previous bought at was USD 12.3679. The current market price is -11.8% lower than average price they were purchased at. The value of the holding in KALV has fallen by USD 1,878 compared to the previous valuation of Kalvista Pharmaceuticals Inc |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 37.01 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 37.01. The average price that KNSA shares were previous bought at was USD 29.3698. The current market price is 26.0% higher than average price they were purchased at. The value of the holding in KNSA has fallen by USD 7,863 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd |
| KROS - Keros Therapeutics Inc | HOLD | 0 @ USD 15.22 | USD 0 | The current share valuation price of KROS based on adjusted close was USD 15.22. The average price that KROS shares were previous bought at was USD 13.6388. The current market price is 11.6% higher than average price they were purchased at. The value of the holding in KROS has increased by USD 4,842 compared to the previous valuation of Keros Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| KRYS - Krystal Biotech Inc | HOLD | 0 @ USD 197.51 | USD 0 | The current share valuation price of KRYS based on adjusted close was USD 197.51. The average price that KRYS shares were previous bought at was USD 159.009. The current market price is 24.2% higher than average price they were purchased at. The value of the holding in KRYS has increased by USD 156,908 compared to the previous valuation of Krystal Biotech Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 10.27 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 10.27. The average price that KURA shares were previous bought at was USD 7.13912. The current market price is 43.9% higher than average price they were purchased at. The value of the holding in KURA has fallen by USD 9,799 compared to the previous valuation of Kura Oncology Inc |
| KYMR - Kymera Therapeutics Inc | HOLD | 0 @ USD 61.84 | USD 0 | The current share valuation price of KYMR based on adjusted close was USD 61.84. The average price that KYMR shares were previous bought at was USD 46.0086. The current market price is 34.4% higher than average price they were purchased at. The value of the holding in KYMR has increased by USD 18,451 compared to the previous valuation of Kymera Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| LEGN - Legend Biotech Corp | HOLD | 0 @ USD 32.4 | USD 0 | The current share valuation price of LEGN based on adjusted close was USD 32.4. The average price that LEGN shares were previous bought at was USD 34.919. The current market price is -7.2% lower than average price they were purchased at. The value of the holding in LEGN has increased by USD 8,114 compared to the previous valuation of Legend Biotech Corp however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 191.31 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 191.31. The average price that LGND shares were previous bought at was USD 130.363. The current market price is 46.8% higher than average price they were purchased at. The value of the holding in LGND has increased by USD 53,813 compared to the previous valuation of Ligand Pharmaceuticals Incorporated however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| LXRX - Lexicon Pharmaceuticals Inc | HOLD | 0 @ USD 1.38 | USD 0 | The current share valuation price of LXRX based on adjusted close was USD 1.38. The average price that LXRX shares were previous bought at was USD 1.03145. The current market price is 33.8% higher than average price they were purchased at. The value of the holding in LXRX has increased by USD 9,632 compared to the previous valuation of Lexicon Pharmaceuticals Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| LYEL - Lyell Immunopharma Inc | HOLD | 0 @ USD 16.66 | USD 0 | The current share valuation price of LYEL based on adjusted close was USD 16.66. The average price that LYEL shares were previous bought at was USD 6.2621. The current market price is 166.0% higher than average price they were purchased at. The value of the holding in LYEL has increased by USD 1,593 compared to the previous valuation of Lyell Immunopharma Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| MDGL - Madrigal Pharmaceuticals Inc | HOLD | 0 @ USD 418.9 | USD 0 | The current share valuation price of MDGL based on adjusted close was USD 418.9. The average price that MDGL shares were previous bought at was USD 341.416. The current market price is 22.7% higher than average price they were purchased at. The value of the holding in MDGL has fallen by USD 123,292 compared to the previous valuation of Madrigal Pharmaceuticals Inc |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 584.91 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 584.91. The average price that MEDP shares were previous bought at was USD 384.652. The current market price is 52.1% higher than average price they were purchased at. The value of the holding in MEDP has increased by USD 82,110 compared to the previous valuation of Medpace Holdings Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| MGNX - MacroGenics Inc | HOLD | 0 @ USD 1.66 | USD 0 | The current share valuation price of MGNX based on adjusted close was USD 1.66. The average price that MGNX shares were previous bought at was USD 1.58218. The current market price is 4.9% higher than average price they were purchased at. The value of the holding in MGNX has increased by USD 2,556 compared to the previous valuation of MacroGenics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| MGTX - MeiraGTx Holdings PLC | HOLD | 0 @ USD 9.08001 | USD 0 | The current share valuation price of MGTX based on adjusted close was USD 9.08001. The average price that MGTX shares were previous bought at was USD 7.18707. The current market price is 26.3% higher than average price they were purchased at. The value of the holding in MGTX has increased by USD 17,958 compared to the previous valuation of MeiraGTx Holdings PLC however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| MIRM - Mirum Pharmaceuticals Inc | HOLD | 0 @ USD 72.65 | USD 0 | The current share valuation price of MIRM based on adjusted close was USD 72.65. The average price that MIRM shares were previous bought at was USD 54.9032. The current market price is 32.3% higher than average price they were purchased at. The value of the holding in MIRM has increased by USD 14,611 compared to the previous valuation of Mirum Pharmaceuticals Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | HOLD | 0 @ USD 40.86 | USD 0 | The current share valuation price of MLYS based on adjusted close was USD 40.86. The average price that MLYS shares were previous bought at was USD 19.1099. The current market price is 113.8% higher than average price they were purchased at. The value of the holding in MLYS has fallen by USD 10,970 compared to the previous valuation of Mineralys Therapeutics, Inc. Common Stock |
| MNKD - MannKind Corp | HOLD | 0 @ USD 5.59 | USD 0 | The current share valuation price of MNKD based on adjusted close was USD 5.59. The average price that MNKD shares were previous bought at was USD 4.70034. The current market price is 18.9% higher than average price they were purchased at. The value of the holding in MNKD has increased by USD 7,821 compared to the previous valuation of MannKind Corp however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| MNMD - Mind Medicine Inc | HOLD | 0 @ USD 14.2 | USD 0 | The current share valuation price of MNMD based on adjusted close was USD 14.2. The average price that MNMD shares were previous bought at was USD 8.47188. The current market price is 67.6% higher than average price they were purchased at. The value of the holding in MNMD has increased by USD 40,009 compared to the previous valuation of Mind Medicine Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| MRNA - Moderna Inc | HOLD | 0 @ USD 27.16 | USD 0 | The current share valuation price of MRNA based on adjusted close was USD 27.16. The average price that MRNA shares were previous bought at was USD 29.4146. The current market price is -7.7% lower than average price they were purchased at. The value of the holding in MRNA has fallen by USD 244,658 compared to the previous valuation of Moderna Inc |
| MRSN - Mersana Therapeutics Inc | HOLD | 0 @ USD 9.58012 | USD 0 | The current share valuation price of MRSN based on adjusted close was USD 9.58012. The average price that MRSN shares were previous bought at was USD 0.52291. The current market price is 1,732.1% higher than average price they were purchased at. The value of the holding in MRSN has increased by USD 843 compared to the previous valuation of Mersana Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| MRUS - Merus BV | HOLD | 0 @ USD 94.86 | USD 0 | The current share valuation price of MRUS based on adjusted close was USD 94.86. The average price that MRUS shares were previous bought at was USD 62.8736. The current market price is 50.9% higher than average price they were purchased at. The value of the holding in MRUS has fallen by USD 9,729 compared to the previous valuation of Merus BV |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 3.14 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 3.14. The average price that MRVI shares were previous bought at was USD 2.68851. The current market price is 16.8% higher than average price they were purchased at. USD 0 compared to the previous valuation of Maravai Lifesciences Holdings Inc |
| MXCT - MaxCyte Inc | HOLD | 0 @ USD 1.54 | USD 0 | The current share valuation price of MXCT based on adjusted close was USD 1.54. The average price that MXCT shares were previous bought at was USD 2.20519. The current market price is -30.2% lower than average price they were purchased at. The value of the holding in MXCT has increased by USD 2,046 compared to the previous valuation of MaxCyte Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 143.21 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 143.21. The average price that NBIX shares were previous bought at was USD 129.224. The current market price is 10.8% higher than average price they were purchased at. The value of the holding in NBIX has increased by USD 330,306 compared to the previous valuation of Neurocrine Biosciences Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| NRIX - Nurix Therapeutics Inc | HOLD | 0 @ USD 12.94 | USD 0 | The current share valuation price of NRIX based on adjusted close was USD 12.94. The average price that NRIX shares were previous bought at was USD 12.0482. The current market price is 7.4% higher than average price they were purchased at. The value of the holding in NRIX has increased by USD 8,196 compared to the previous valuation of Nurix Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| NTLA - Intellia Therapeutics Inc | HOLD | 0 @ USD 12.62 | USD 0 | The current share valuation price of NTLA based on adjusted close was USD 12.62. The average price that NTLA shares were previous bought at was USD 12.5369. The current market price is 0.7% higher than average price they were purchased at. The value of the holding in NTLA has increased by USD 24,580 compared to the previous valuation of Intellia Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| NUVL - Nuvalent Inc | HOLD | 0 @ USD 99.32 | USD 0 | The current share valuation price of NUVL based on adjusted close was USD 99.32. The average price that NUVL shares were previous bought at was USD 81.4946. The current market price is 21.9% higher than average price they were purchased at. The value of the holding in NUVL has increased by USD 49,259 compared to the previous valuation of Nuvalent Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| NVAX - Novavax Inc | HOLD | 0 @ USD 8.4 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 8.4. The average price that NVAX shares were previous bought at was USD 7.38242. The current market price is 13.8% higher than average price they were purchased at. The value of the holding in NVAX has fallen by USD 3,105 compared to the previous valuation of Novavax Inc |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 8.4 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 8.4. The average price that NVAX shares were previous bought at was USD 7.38242. The current market price is 13.8% higher than average price they were purchased at. The value of the holding in NVAX has fallen by USD 3,105 compared to the previous valuation of Hana Microelectronics Public Company Limited |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 12.81 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 12.81. The average price that NVCR shares were previous bought at was USD 16.8672. The current market price is -24.1% lower than average price they were purchased at. The value of the holding in NVCR has fallen by USD 713 compared to the previous valuation of Novocure Ltd |
| OABI - OmniAb Inc. | HOLD | 0 @ USD 1.55 | USD 0 | The current share valuation price of OABI based on adjusted close was USD 1.55. The average price that OABI shares were previous bought at was USD 1.9323. The current market price is -19.8% lower than average price they were purchased at. The value of the holding in OABI has increased by USD 4,719 compared to the previous valuation of OmniAb Inc. however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| OCUL - Ocular Therapeutix Inc | HOLD | 0 @ USD 11.66 | USD 0 | The current share valuation price of OCUL based on adjusted close was USD 11.66. The average price that OCUL shares were previous bought at was USD 9.93678. The current market price is 17.3% higher than average price they were purchased at. The value of the holding in OCUL has fallen by USD 17,727 compared to the previous valuation of Ocular Therapeutix Inc |
| OKUR - OKUR | HOLD | 0 @ USD 3.38998 | USD 0 | The current share valuation price of OKUR based on adjusted close was USD 3.38998. The average price that OKUR shares were previous bought at was USD 6.13912. The current market price is -44.8% lower than average price they were purchased at. The value of the holding in OKUR has increased by USD 310 compared to the previous valuation of OKUR however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| OLMA - Olema Pharmaceuticals Inc | HOLD | 0 @ USD 8.97001 | USD 0 | The current share valuation price of OLMA based on adjusted close was USD 8.97001. The average price that OLMA shares were previous bought at was USD 5.45228. The current market price is 64.5% higher than average price they were purchased at. The value of the holding in OLMA has increased by USD 8,160 compared to the previous valuation of Olema Pharmaceuticals Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| ORIC - Oric Pharmaceuticals Inc | HOLD | 0 @ USD 13.16 | USD 0 | The current share valuation price of ORIC based on adjusted close was USD 13.16. The average price that ORIC shares were previous bought at was USD 10.4489. The current market price is 25.9% higher than average price they were purchased at. The value of the holding in ORIC has fallen by USD 11,132 compared to the previous valuation of Oric Pharmaceuticals Inc |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 2.34 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 2.34. The average price that PACB shares were previous bought at was USD 1.53703. The current market price is 52.2% higher than average price they were purchased at. The value of the holding in PACB has increased by USD 80,773 compared to the previous valuation of Pacific Biosciences of California however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| PAHC - Phibro Animal Health Corporation | HOLD | 0 @ USD 42.06 | USD 0 | The current share valuation price of PAHC based on adjusted close was USD 42.06. The average price that PAHC shares were previous bought at was USD 28.1774. The current market price is 49.3% higher than average price they were purchased at. The value of the holding in PAHC has increased by USD 2,564 compared to the previous valuation of Phibro Animal Health Corporation however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| PCRX - Pacira BioSciences, Inc. | HOLD | 0 @ USD 21.38 | USD 0 | The current share valuation price of PCRX based on adjusted close was USD 21.38. The average price that PCRX shares were previous bought at was USD 23.8049. The current market price is -10.2% lower than average price they were purchased at. The value of the holding in PCRX has increased by USD 3,148 compared to the previous valuation of Pacira BioSciences, Inc. however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| PCVX - Vaxcyte Inc | HOLD | 0 @ USD 45.28 | USD 0 | The current share valuation price of PCVX based on adjusted close was USD 45.28. The average price that PCVX shares were previous bought at was USD 44.4131. The current market price is 2.0% higher than average price they were purchased at. The value of the holding in PCVX has increased by USD 44,243 compared to the previous valuation of Vaxcyte Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| PGEN - Precigen Inc | HOLD | 0 @ USD 4.14 | USD 0 | The current share valuation price of PGEN based on adjusted close was USD 4.14. The average price that PGEN shares were previous bought at was USD 2.20737. The current market price is 87.6% higher than average price they were purchased at. The value of the holding in PGEN has increased by USD 17,477 compared to the previous valuation of Precigen Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| PHAT - Phathom Pharmaceuticals Inc | HOLD | 0 @ USD 13.55 | USD 0 | The current share valuation price of PHAT based on adjusted close was USD 13.55. The average price that PHAT shares were previous bought at was USD 8.79787. The current market price is 54.0% higher than average price they were purchased at. The value of the holding in PHAT has increased by USD 11,070 compared to the previous valuation of Phathom Pharmaceuticals Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| PLRX - Pliant Therapeutics Inc | HOLD | 0 @ USD 1.67999 | USD 0 | The current share valuation price of PLRX based on adjusted close was USD 1.67999. The average price that PLRX shares were previous bought at was USD 1.48983. The current market price is 12.8% higher than average price they were purchased at. The value of the holding in PLRX has increased by USD 1,484 compared to the previous valuation of Pliant Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| PRAX - Praxis Precision Medicines Inc | HOLD | 0 @ USD 198.76 | USD 0 | The current share valuation price of PRAX based on adjusted close was USD 198.76. The average price that PRAX shares were previous bought at was USD 58.8904. The current market price is 237.5% higher than average price they were purchased at. The value of the holding in PRAX has fallen by USD 30,381 compared to the previous valuation of Praxis Precision Medicines Inc |
| PRME - Prime Medicine, Inc. Common Stock | HOLD | 0 @ USD 4.94 | USD 0 | The current share valuation price of PRME based on adjusted close was USD 4.94. The average price that PRME shares were previous bought at was USD 4.56553. The current market price is 8.2% higher than average price they were purchased at. The value of the holding in PRME has increased by USD 65,726 compared to the previous valuation of Prime Medicine, Inc. Common Stock however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| PRTA - Prothena Corporation plc | HOLD | 0 @ USD 10.75 | USD 0 | The current share valuation price of PRTA based on adjusted close was USD 10.75. The average price that PRTA shares were previous bought at was USD 8.93485. The current market price is 20.3% higher than average price they were purchased at. The value of the holding in PRTA has increased by USD 9,454 compared to the previous valuation of Prothena Corporation plc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 68.31 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 68.31. The average price that PTCT shares were previous bought at was USD 54.1247. The current market price is 26.2% higher than average price they were purchased at. The value of the holding in PTCT has increased by USD 10,219 compared to the previous valuation of PTC Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| PTGX - Protagonist Therapeutics Inc | HOLD | 0 @ USD 78.62 | USD 0 | The current share valuation price of PTGX based on adjusted close was USD 78.62. The average price that PTGX shares were previous bought at was USD 55.6365. The current market price is 41.3% higher than average price they were purchased at. The value of the holding in PTGX has increased by USD 30,889 compared to the previous valuation of Protagonist Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| QURE - Uniqure NV | HOLD | 0 @ USD 67.69 | USD 0 | The current share valuation price of QURE based on adjusted close was USD 67.69. The average price that QURE shares were previous bought at was USD 22.7658. The current market price is 197.3% higher than average price they were purchased at. The value of the holding in QURE has fallen by USD 5,985 compared to the previous valuation of Uniqure NV |
| RARE - Ultragenyx | HOLD | 0 @ USD 34.6 | USD 0 | The current share valuation price of RARE based on adjusted close was USD 34.6. The average price that RARE shares were previous bought at was USD 36.4253. The current market price is -5.0% lower than average price they were purchased at. The value of the holding in RARE has fallen by USD 35,621 compared to the previous valuation of Ultragenyx |
| RARE - WISETFWTMRARETFP | HOLD | 0 @ USD 34.6 | USD 0 | The current share valuation price of RARE based on adjusted close was USD 34.6. The average price that RARE shares were previous bought at was USD 36.4253. The current market price is -5.0% lower than average price they were purchased at. The value of the holding in RARE has fallen by USD 35,621 compared to the previous valuation of WISETFWTMRARETFP |
| RCKT - Rocket Pharmaceuticals Inc | HOLD | 0 @ USD 3.77001 | USD 0 | The current share valuation price of RCKT based on adjusted close was USD 3.77001. The average price that RCKT shares were previous bought at was USD 5.17569. The current market price is -27.2% lower than average price they were purchased at. The value of the holding in RCKT has increased by USD 4,768 compared to the previous valuation of Rocket Pharmaceuticals Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 651.8 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 651.8. The average price that REGN shares were previous bought at was USD 625.052. The current market price is 4.3% higher than average price they were purchased at. The value of the holding in REGN has fallen by USD 148,835 compared to the previous valuation of Regeneron Pharmaceuticals Inc |
| REPL - Replimune Group Inc | HOLD | 0 @ USD 9.72999 | USD 0 | The current share valuation price of REPL based on adjusted close was USD 9.72999. The average price that REPL shares were previous bought at was USD 8.86462. The current market price is 9.8% higher than average price they were purchased at. The value of the holding in REPL has fallen by USD 26,504 compared to the previous valuation of Replimune Group Inc |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 12.77 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 12.77. The average price that RGNX shares were previous bought at was USD 9.08069. The current market price is 40.6% higher than average price they were purchased at. The value of the holding in RGNX has fallen by USD 1,674 compared to the previous valuation of Regenxbio Inc |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 7.14 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 7.14. The average price that RLAY shares were previous bought at was USD 4.09041. The current market price is 74.6% higher than average price they were purchased at. The value of the holding in RLAY has fallen by USD 21,988 compared to the previous valuation of Relay Therapeutics Inc |
| RNA - Avidity Biosciences Inc | HOLD | 0 @ USD 69.85 | USD 0 | The current share valuation price of RNA based on adjusted close was USD 69.85. The average price that RNA shares were previous bought at was USD 35.8413. The current market price is 94.9% higher than average price they were purchased at. The value of the holding in RNA has increased by USD 13,209 compared to the previous valuation of Avidity Biosciences Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| ROIV - Roivant Sciences Ltd | HOLD | 0 @ USD 19.99 | USD 0 | The current share valuation price of ROIV based on adjusted close was USD 19.99. The average price that ROIV shares were previous bought at was USD 12.5575. The current market price is 59.2% higher than average price they were purchased at. The value of the holding in ROIV has increased by USD 179,645 compared to the previous valuation of Roivant Sciences Ltd however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 37.54 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 37.54. The average price that RPRX shares were previous bought at was USD 35.4091. The current market price is 6.0% higher than average price they were purchased at. The value of the holding in RPRX has increased by USD 166,422 compared to the previous valuation of Royalty Pharma Plc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| RVMD - Revolution Medicines Inc | HOLD | 0 @ USD 58.84 | USD 0 | The current share valuation price of RVMD based on adjusted close was USD 58.84. The average price that RVMD shares were previous bought at was USD 40.735. The current market price is 44.4% higher than average price they were purchased at. The value of the holding in RVMD has fallen by USD 3,617 compared to the previous valuation of Revolution Medicines Inc |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 5.52 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 5.52. The average price that RXRX shares were previous bought at was USD 5.81427. The current market price is -5.1% lower than average price they were purchased at. The value of the holding in RXRX has fallen by USD 36,011 compared to the previous valuation of Recursion Pharmaceuticals Inc |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 113.76 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 113.76. The average price that RYTM shares were previous bought at was USD 74.6819. The current market price is 52.3% higher than average price they were purchased at. The value of the holding in RYTM has increased by USD 83,552 compared to the previous valuation of Rhythm Pharmaceuticals Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| SANA - Sana Biotechnology Inc | HOLD | 0 @ USD 4.95 | USD 0 | The current share valuation price of SANA based on adjusted close was USD 4.95. The average price that SANA shares were previous bought at was USD 3.20006. The current market price is 54.7% higher than average price they were purchased at. The value of the holding in SANA has increased by USD 8,371 compared to the previous valuation of Sana Biotechnology Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| SIGA - SIGA Technologies Inc | HOLD | 0 @ USD 8.28001 | USD 0 | The current share valuation price of SIGA based on adjusted close was USD 8.28001. The average price that SIGA shares were previous bought at was USD 6.80881. The current market price is 21.6% higher than average price they were purchased at. The value of the holding in SIGA has fallen by USD 1,345 compared to the previous valuation of SIGA Technologies Inc |
| SMMT - Summit Therapeutics PLC | HOLD | 0 @ USD 18.91 | USD 0 | The current share valuation price of SMMT based on adjusted close was USD 18.91. The average price that SMMT shares were previous bought at was USD 21.6026. The current market price is -12.5% lower than average price they were purchased at. The value of the holding in SMMT has increased by USD 129,204 compared to the previous valuation of Summit Therapeutics PLC however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| SNDX - Syndax Pharmaceuticals Inc | HOLD | 0 @ USD 13.7 | USD 0 | The current share valuation price of SNDX based on adjusted close was USD 13.7. The average price that SNDX shares were previous bought at was USD 11.4892. The current market price is 19.2% higher than average price they were purchased at. The value of the holding in SNDX has increased by USD 17,017 compared to the previous valuation of Syndax Pharmaceuticals Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| SNY - Sanofi ADR | HOLD | 0 @ USD 50.58 | USD 0 | The current share valuation price of SNY based on adjusted close was USD 50.58. The average price that SNY shares were previous bought at was USD 49.9862. The current market price is 1.2% higher than average price they were purchased at. The value of the holding in SNY has fallen by USD 62,237 compared to the previous valuation of Sanofi ADR |
| SPRY - Silverback Therapeutics Inc | HOLD | 0 @ USD 8.96 | USD 0 | The current share valuation price of SPRY based on adjusted close was USD 8.96. The average price that SPRY shares were previous bought at was USD 13.9399. The current market price is -35.7% lower than average price they were purchased at. The value of the holding in SPRY has increased by USD 21,180 compared to the previous valuation of Silverback Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 24.01 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 24.01. The average price that SRPT shares were previous bought at was USD 34.5337. The current market price is -30.5% lower than average price they were purchased at. The value of the holding in SRPT has increased by USD 47,280 compared to the previous valuation of Sarepta Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| SRRK - Scholar Rock Holding Corp | HOLD | 0 @ USD 29.62 | USD 0 | The current share valuation price of SRRK based on adjusted close was USD 29.62. The average price that SRRK shares were previous bought at was USD 35.1053. The current market price is -15.6% lower than average price they were purchased at. The value of the holding in SRRK has increased by USD 15,513 compared to the previous valuation of Scholar Rock Holding Corp however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 30.04 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 30.04. The average price that STOK shares were previous bought at was USD 15.3819. The current market price is 95.3% higher than average price they were purchased at. The value of the holding in STOK has fallen by USD 59,141 compared to the previous valuation of Stoke Therapeutics Inc |
| STRO - Sutro Biopharma | HOLD | 0 @ USD 1.12 | USD 0 | The current share valuation price of STRO based on adjusted close was USD 1.12. The average price that STRO shares were previous bought at was USD 0.90011. The current market price is 24.4% higher than average price they were purchased at. The value of the holding in STRO has fallen by USD 2,011 compared to the previous valuation of Sutro Biopharma |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 55.13 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 55.13. The average price that SUPN shares were previous bought at was USD 37.0203. The current market price is 48.9% higher than average price they were purchased at. The value of the holding in SUPN has fallen by USD 49,892 compared to the previous valuation of Supernus Pharmaceuticals Inc |
| SVRA - Savara Inc | HOLD | 0 @ USD 4.15 | USD 0 | The current share valuation price of SVRA based on adjusted close was USD 4.15. The average price that SVRA shares were previous bought at was USD 2.74368. The current market price is 51.3% higher than average price they were purchased at. The value of the holding in SVRA has fallen by USD 16,450 compared to the previous valuation of Savara Inc |
| SYRE - Spyre Therapeutics Inc. | HOLD | 0 @ USD 24.46 | USD 0 | The current share valuation price of SYRE based on adjusted close was USD 24.46. The average price that SYRE shares were previous bought at was USD 17.3114. The current market price is 41.3% higher than average price they were purchased at. The value of the holding in SYRE has increased by USD 7,658 compared to the previous valuation of Spyre Therapeutics Inc. however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| TARS - Tarsus Pharmaceuticals Inc | HOLD | 0 @ USD 68.81 | USD 0 | The current share valuation price of TARS based on adjusted close was USD 68.81. The average price that TARS shares were previous bought at was USD 48.2502. The current market price is 42.6% higher than average price they were purchased at. The value of the holding in TARS has fallen by USD 4,105 compared to the previous valuation of Tarsus Pharmaceuticals Inc |
| TBPH - Theravance Biopharma Inc | HOLD | 0 @ USD 14.66 | USD 0 | The current share valuation price of TBPH based on adjusted close was USD 14.66. The average price that TBPH shares were previous bought at was USD 11.5918. The current market price is 26.5% higher than average price they were purchased at. The value of the holding in TBPH has increased by USD 11,559 compared to the previous valuation of Theravance Biopharma Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| TERN - Tern Plc | HOLD | 0 @ USD 8.26 | USD 0 | The current share valuation price of TERN based on adjusted close was USD 8.26. The average price that TERN shares were previous bought at was USD 5.12922. The current market price is 61.0% higher than average price they were purchased at. The value of the holding in TERN has increased by USD 5,582 compared to the previous valuation of Tern Plc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.06885. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| TNGX - Tango Therapeutics Inc | HOLD | 0 @ USD 8.11 | USD 0 | The current share valuation price of TNGX based on adjusted close was USD 8.11. The average price that TNGX shares were previous bought at was USD 6.08872. The current market price is 33.2% higher than average price they were purchased at. The value of the holding in TNGX has increased by USD 9,920 compared to the previous valuation of Tango Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| TRDA - Entrada Therapeutics Inc | HOLD | 0 @ USD 6.95 | USD 0 | The current share valuation price of TRDA based on adjusted close was USD 6.95. The average price that TRDA shares were previous bought at was USD 7.63452. The current market price is -9.0% lower than average price they were purchased at. The value of the holding in TRDA has increased by USD 1,305 compared to the previous valuation of Entrada Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| TSHA - Taysha Gene Therapies Inc | HOLD | 0 @ USD 4.96 | USD 0 | The current share valuation price of TSHA based on adjusted close was USD 4.96. The average price that TSHA shares were previous bought at was USD 2.83993. The current market price is 74.7% higher than average price they were purchased at. The value of the holding in TSHA has increased by USD 8,696 compared to the previous valuation of Taysha Gene Therapies Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| TVTX - Travere Therapeutics Inc | HOLD | 0 @ USD 35.16 | USD 0 | The current share valuation price of TVTX based on adjusted close was USD 35.16. The average price that TVTX shares were previous bought at was USD 19.2334. The current market price is 82.8% higher than average price they were purchased at. The value of the holding in TVTX has increased by USD 312,731 compared to the previous valuation of Travere Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 32.89 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 32.89. The average price that TWST shares were previous bought at was USD 36.5031. The current market price is -9.9% lower than average price they were purchased at. The value of the holding in TWST has increased by USD 66,131 compared to the previous valuation of Twist Bioscience Corp however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 13.64 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 13.64. The average price that TXG shares were previous bought at was USD 12.0209. The current market price is 13.5% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 88,415 compared to the previous valuation of 10X Genomics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| TXG - Terex Corporation | HOLD | 0 @ USD 13.64 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 13.64. The average price that TXG shares were previous bought at was USD 12.0209. The current market price is 13.5% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 88,415 compared to the previous valuation of Terex Corporation however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| URGN - UroGen Pharma Ltd | HOLD | 0 @ USD 20.47 | USD 0 | The current share valuation price of URGN based on adjusted close was USD 20.47. The average price that URGN shares were previous bought at was USD 14.524. The current market price is 40.9% higher than average price they were purchased at. The value of the holding in URGN has increased by USD 18,943 compared to the previous valuation of UroGen Pharma Ltd however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 445.43 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 445.43. The average price that UTHR shares were previous bought at was USD 338.369. The current market price is 31.6% higher than average price they were purchased at. The value of the holding in UTHR has fallen by USD 235,775 compared to the previous valuation of United Therapeutics Corporation |
| VCEL - Vericel Corp Ord | HOLD | 0 @ USD 35.06 | USD 0 | The current share valuation price of VCEL based on adjusted close was USD 35.06. The average price that VCEL shares were previous bought at was USD 40.8192. The current market price is -14.1% lower than average price they were purchased at. The value of the holding in VCEL has increased by USD 17,032 compared to the previous valuation of Vericel Corp Ord however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 36.08 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 36.08. The average price that VCYT shares were previous bought at was USD 30.8257. The current market price is 17.0% higher than average price they were purchased at. The value of the holding in VCYT has increased by USD 38,334 compared to the previous valuation of Veracyte Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| VERA - Vera Therapeutics Inc | HOLD | 0 @ USD 28.46 | USD 0 | The current share valuation price of VERA based on adjusted close was USD 28.46. The average price that VERA shares were previous bought at was USD 26.7652. The current market price is 6.3% higher than average price they were purchased at. The value of the holding in VERA has fallen by USD 49,172 compared to the previous valuation of Vera Therapeutics Inc |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 5.96 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.96. The average price that VIR shares were previous bought at was USD 5.84471. The current market price is 2.0% higher than average price they were purchased at. The value of the holding in VIR has increased by USD 2,638 compared to the previous valuation of Vir Biotechnology Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| VIR - Vidrala S.A | HOLD | 0 @ USD 5.96 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.96. The average price that VIR shares were previous bought at was USD 5.84471. The current market price is 2.0% higher than average price they were purchased at. The value of the holding in VIR has increased by USD 2,638 compared to the previous valuation of Vidrala S.A however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| VRTX - Vertex Pharmaceuticals Inc | HOLD | 0 @ USD 425.57 | USD 0 | The current share valuation price of VRTX based on adjusted close was USD 425.57. The average price that VRTX shares were previous bought at was USD 414.896. The current market price is 2.6% higher than average price they were purchased at. The value of the holding in VRTX has increased by USD 773,094 compared to the previous valuation of Vertex Pharmaceuticals Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| VTRS - Viatris Inc | HOLD | 0 @ USD 10.36 | USD 0 | The current share valuation price of VTRS based on adjusted close was USD 10.36. The average price that VTRS shares were previous bought at was USD 9.54506. The current market price is 8.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of Viatris Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| VYGR - Voyager Therapeutics Inc | HOLD | 0 @ USD 4.66999 | USD 0 | The current share valuation price of VYGR based on adjusted close was USD 4.66999. The average price that VYGR shares were previous bought at was USD 3.83071. The current market price is 21.9% higher than average price they were purchased at. The value of the holding in VYGR has increased by USD 4,919 compared to the previous valuation of Voyager Therapeutics Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| WVE - Wave Life Sciences Ltd | HOLD | 0 @ USD 9.04 | USD 0 | The current share valuation price of WVE based on adjusted close was USD 9.04. The average price that WVE shares were previous bought at was USD 8.46359. The current market price is 6.8% higher than average price they were purchased at. The value of the holding in WVE has increased by USD 76,917 compared to the previous valuation of Wave Life Sciences Ltd however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| XENE - Xenon Pharmaceuticals Inc | HOLD | 0 @ USD 41.92 | USD 0 | The current share valuation price of XENE based on adjusted close was USD 41.92. The average price that XENE shares were previous bought at was USD 35.3656. The current market price is 18.5% higher than average price they were purchased at. The value of the holding in XENE has fallen by USD 37,465 compared to the previous valuation of Xenon Pharmaceuticals Inc |
| XERS - Xeris Pharmaceuticals Inc | HOLD | 0 @ USD 9.7 | USD 0 | The current share valuation price of XERS based on adjusted close was USD 9.7. The average price that XERS shares were previous bought at was USD 5.9987. The current market price is 61.7% higher than average price they were purchased at. The value of the holding in XERS has fallen by USD 1,060 compared to the previous valuation of Xeris Pharmaceuticals Inc |
| XNCR - Xencor Inc | HOLD | 0 @ USD 14.71 | USD 0 | The current share valuation price of XNCR based on adjusted close was USD 14.71. The average price that XNCR shares were previous bought at was USD 11.0259. The current market price is 33.4% higher than average price they were purchased at. The value of the holding in XNCR has increased by USD 26,365 compared to the previous valuation of Xencor Inc however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| ZLAB - Zai Lab Ltd | HOLD | 0 @ USD 26.13 | USD 0 | The current share valuation price of ZLAB based on adjusted close was USD 26.13. The average price that ZLAB shares were previous bought at was USD 34.2923. The current market price is -23.8% lower than average price they were purchased at. The value of the holding in ZLAB has increased by USD 18,583 compared to the previous valuation of Zai Lab Ltd however if the holding was sold on 2025-10-31 this would crystalise an overall loss. |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 19.085 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 19.085. The average price that ZYME shares were previous bought at was USD 14.1552. The current market price is 34.8% higher than average price they were purchased at. The value of the holding in ZYME has fallen by USD 1,726 compared to the previous valuation of Zymeworks Inc. Common Stock |